Isibindi esinamafutha esingesona isidakwa siyingozi yomdlavuza wesibindi

Yabelana ngalokhu okuthunyelwe

Nonalcoholic fatty liver disease (NAFLD) is a very common disease. To better understand the link between NAFLD and hepatocellular carcinoma (HCC) risk, researchers at Baylor College of Medicine conducted a large Retrospective study published in “Gastroenterology”.

In this study, the research team studied groups from the Veterans Health Administration and followed up for about 11 years. The study included 296,707 patients known to have NAFLD and 296,707 patients without NAFLD. Among NAFLD patients, 490 have HCC, and their risk of developing HCC is much higher than those without NAFLD.

Dr. Fasiha Kanwal, professor and chief of medicine, and colleagues found that NAFLD patients with liver cirrhosis have the highest incidence of HCC each year. The risk of HCC increases with age, and the elderly Spanish with liver cirrhosis is HCC High-risk groups.

“This study provides valuable and powerful information on which of the millions of NAFLD patients are at risk for HCC. This information is an important step forward in our understanding of the disease. For researchers, clinical Doctors and patients have important reference value, ” said Dr. Hashem EI-Serag, professor of gastroenterology at Baylor Medicine and senior author of the paper . Moreover, the results of this study also provide guidance for monitoring and risk adjustment for people at increased risk of umdlavuza wesibindi, such as patients with cirrhosis or diabetes.

Bhalisa ku-Newsletter yethu

Thola izibuyekezo futhi ungalokothi uphuthelwe ibhulogi evela kuCancerfax

Okuningi Okuzohlolwa

I-CAR T Cell Therapy Esekelwe Kubantu: Ukuphumelela Nezinselele
Ukwelashwa kwe-CAR T-Cell

I-CAR T Cell Therapy Esekelwe Kubantu: Ukuphumelela kanye Nezinselele

Ukwelashwa kwe-CAR T-cell okusekelwe kumuntu kuguqula ukwelashwa komdlavuza ngokushintsha izakhi zofuzo amaseli omzimba esiguli ukuze aqondise futhi abhubhise amaseli omdlavuza. Ngokusebenzisa amandla esimiso somzimba sokuzivikela ezifweni, lezi zindlela zokwelapha zinikeza ukwelashwa okunamandla futhi okuqondene nomuntu okungahle kube nokuxolelwa okuhlala isikhathi eside ezinhlotsheni ezihlukahlukene zomdlavuza.

Ukuqonda I-Cytokine Release Syndrome: Izimbangela, Izimpawu, Nokwelashwa
Ukwelashwa kwe-CAR T-Cell

Ukuqonda I-Cytokine Release Syndrome: Izimbangela, Izimpawu, Nokwelashwa

I-Cytokine Release Syndrome (CRS) iwukusabela kwamasosha omzimba okuvame ukubangelwa izindlela zokwelapha ezithile ezifana ne-immunotherapy noma i-CAR-T cell therapy. Kuhilela ukukhululwa ngokweqile kwama-cytokines, okubangela izimpawu ezisukela kumkhuhlane nokukhathala kuya ezinkingeni ezingase zibeke ukuphila engozini njengokulimala kwesitho. Ukuphatha kudinga ukuqapha ngokucophelela kanye namasu okungenelela.

Dinga usizo? Ithimba lethu likulungele ukukusiza.

Sifisela ukululama okusheshayo kothandekayo wakho futhi oseduze.

Qala ingxoxo
Siku-inthanethi! Xoxa Nathi!
Skena ikhodi
Sawubona,

Siyakwamukela kuCancerFax!

ICancerFax iyinkundla yokuphayona ezinikele ekuxhumaniseni abantu ababhekene nomdlavuza oseqophelweni eliphezulu ngemithi yokwelapha yamangqamuzana efana ne-CAR T-Cell therapy, ukwelashwa kwe-TIL, nezivivinyo zomtholampilo emhlabeni wonke.

Sazise ukuthi yini esingakwenzela yona.

1) Ukwelashwa komdlavuza phesheya?
2) Ukwelashwa kwe-CAR T-Cell
3) Umuthi wokugomela umdlavuza
4) Ukubonisana ngevidiyo eku-inthanethi
5) Ukwelashwa kweProton